- Home
- REGN vs MPWR Comparison
REGN vs MPWR Comparison
Compare REGN & MPWR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | REGN | MPWR |
|---|---|---|
| Founded | 1988 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Semiconductors |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 73.2B | 66.5B |
| IPO Year | 1995 | 2004 |
Fundamental Metrics
Financial Performance| Metric | REGN | MPWR |
|---|---|---|
| Price | $638.39 | $1,518.43 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 25 | 14 |
| Target Price | $830.16 | ★ $1,137.21 |
| AVG Volume (30 Days) | ★ 1.0M | 547.5K |
| Earning Date | 04-29-2026 | 04-30-2026 |
| Dividend Yield | ★ 0.55% | 0.52% |
| EPS Growth | ★ 8.19 | N/A |
| EPS | ★ 6.75 | 3.92 |
| Revenue | ★ $5,872,227,000.00 | $333,067,000.00 |
| Revenue This Year | $12.45 | $23.89 |
| Revenue Next Year | $10.13 | $17.62 |
| P/E Ratio | ★ $93.13 | $421.50 |
| Revenue Growth | ★ 20.82 | 17.89 |
| 52 Week Low | $494.42 | $670.00 |
| 52 Week High | $821.11 | $1,714.09 |
Technical Indicators
Market Signals| Indicator | REGN | MPWR |
|---|---|---|
| Relative Strength Index (RSI) | 42.17 | 46.74 |
| Support Level | $610.60 | $1,450.46 |
| Resistance Level | $783.87 | $1,683.77 |
| Average True Range (ATR) | 15.40 | 80.29 |
| MACD | 1.54 | -10.08 |
| Stochastic Oscillator | 80.31 | 34.99 |
Price Performance
Historical ComparisonAbout REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.
About MPWR Monolithic Power Systems Inc.
Monolithic Power Systems is an analog and mixed-signal chipmaker specializing in power management solutions. Its mission is to reduce total energy consumption in end systems. It serves the computing, automotive, industrial, communications, and consumer end markets. MPS uses a fabless manufacturing model, partnering with third-party chip foundries to host its proprietary BCD process technology.